Monday, May 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

NIH Announces Action Plan to Fix Issues at Clinical Center

by Global Biodefense Staff
June 22, 2015
Current Good Manufacturing Practice (CGMP)

A contamination scare at the U.S. National Institutes of Health (NIH) Clinical Center resulted in operations being suspended at the facility on June 4.

Now the NIH has submitted interim corrective action plans to the U.S. Food and Drug Administration (FDA) to address problems with sterile manufacturing processes.

The actions are primarily focused on fixing problems in the Pharmaceutical Development Section (PDS),  and deficiencies of lesser significance in its pharmacy. The issues were uncovered during an FDA inspection at the facility

“NIH takes this issue very seriously and senior leadership took swift action to ensure the safety of research participants,” said the NIH in a statement. “As corrective action is taken to remedy the situation, NIH will continue to take every measure to protect patients and provide access to needed treatments.”

As part of the plan, NIH will hire a contracting firm experienced in Current Good Manufacturing Practice (CGMP) regulations and procedures. The firm will provide a full evaluation of the PDS operations and make recommendations for improvement and for addressing all FDA concerns.

NIH will also establish an external group of advisors with expertise in CGMP-facility management, clinical research, engineering and regulatory requirements to consider the recommendations of the contractor and oversee the implementation of the corrective actions. The plan outlines an aggressive timeline to achieve key milestones by the end of September 2015.

The Clinical Center will not resume sterile products production until all observations are addressed and the facility is inspected by an independent organization to establish that the PDS can meet current cGMP standards and FDA agrees that production should resume.

Tags: NIH

Related Posts

DARPA Pursues Advanced Threat-Detection for Crop Defense
Biosecurity

DARPA Pursues Advanced Threat-Detection for Crop Defense

January 3, 2023
Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.
Policy + Initiatives

Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.

December 7, 2022
Study: Cash Incentives and Lotteries Do Little to Increase Adult Vaccinations
Medical Countermeasures

Study: Cash Incentives and Lotteries Do Little to Increase Adult Vaccinations

October 25, 2022
Black Veterans Hospitalized with COVID-19 Less Likely to Receive Treatments Than White Veterans
Public Health

Black Veterans Hospitalized with COVID-19 Less Likely to Receive Treatments Than White Veterans

October 25, 2022
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC